

**Health Care Cabinet
Pharmacy Pricing Workgroup
Meeting Summary**

Wednesday, August 9, 2017

3:00 PM - 4:30 PM

Web Meeting/Conference Call

Members Present: *Chair* - Josh Wojcik, Policy Director, Office of the State Comptroller; Ellen Andrews, Executive Director, CT Health Policy Project; Bob Clark, Special Counsel to the Attorney General, Office of the Attorney General; Sarah Emond, Executive Vice President and Chief Operating Officer, Institute for Clinical and Economic Review (ICER); Marghie Giuliano, Executive Vice President, CT Pharmacists Association; Anne Foley, Under Secretary, Office of Policy and Management.

Other Participants: Kelly Sinko, Policy Development Coordinator, Office of Policy and Management; Ken Hiscoe, Pfizer; Anita Schepker, Schepker & Associates, LLC; Joni Arvai, Bristol-Myers Squibb Company.

1. Welcome and Introductions

The Chair opened the meeting at 3:05 p.m. and participants introduced themselves.

2. Public Comment

Kevin Hiscoe from Pfizer asked if industry representatives or individual companies that would potentially be affected by any value-based purchasing policies would be able to have an opportunity to present to the workgroup. The Chair supported the idea of including additional presentations and stated that would be discussed later in the agenda.

3. Presentation on Value Based Purchasing Arrangements &

4. Discussion

Sarah Emond, Executive Vice President and Chief Operating Officer of Institute for Clinical and Economic Review (ICER) gave a [presentation](#) on several types of value-based purchasing strategies: outcomes-based contracting, indication-specific pricing, value-based pricing, and value-based formulary design and coverage policies. The presentation included a brief description of each potential policy, existing models where the policy has been implemented, the feasibility of the policy resulting in desired outcomes, and challenges or barriers for consideration.

5. Next Steps

The group discussed next steps to meet the October timeline for presenting recommendations to the Health Care Cabinet. Future meetings will continue to include fact-finding, which will inform a potential draft set of recommendations by the end of September. These draft recommendations will then be honed down by the group and finalized for the October deadline.

The following entities will be asked to present in future meetings, specifically focusing on the list of questions the workgroup developed in their charge:

- State Medicaid Alternative Reimbursement and Purchasing Test for High-Cost Drugs (SMART-D)
- Harvard Pilgrim
- Pharmaceutical manufacturers with Connecticut presence

It was also decided that the examination of Value-Based Formulary Design would be added to the workgroup's charge.

The Chair will follow up with members to schedule the next meeting date.

6. Adjournment

The Chair adjourned the meeting at 4:30 p.m.